CytomX Therapeutics Interest Expense | CTMX

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense CytomX Therapeutics

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
28 K	-38 K	-30 K	340 K	7 K	-29 K	-135 K	-68 K	-27 K	1.69 M	1.73 M	487 K	254 K	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
1.73 M	-135 K	324 K

Quarterly Interest Expense CytomX Therapeutics

2026-Q2	2026-Q1	2025-Q3	2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
18 K	-7 K	5 K	17 K	11 K	-7 K	-2 K	-11 K	-7 K	-47 K	15 K	-	30 K	296 K	13 K	-	-13 K	-82 K	5 K	-	-15 K	5 K	12 K	-	22 K	-88 K	-61 K	-	29 K	61 K	-140 K	-	-47 K	-174 K	206 K	-	482 K	465 K	353 K	-	718 K	408 K	230 K	-	117 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
718 K	-174 K	78.2 K

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
Celsion Corporation CLSN	197 K	-	-6.63 %	$ 13.9 M	USA
FSD Pharma HUGE	9.34 K	-	5743.5 %	$ 69.7 M	Canada
Qilian International Holding Group Limited QLI	555 K	-	-6.08 %	$ 184 M	China
Happiness Biotech Group Limited HAPP	262 K	-	1.35 %	$ 17.8 M	China
Synthetic Biologics SYN	95 K	-	1.32 %	$ 16.2 M	USA
Dynavax Technologies Corporation DVAX	293 K	-	-	$ 2.02 B	USA
BioXcel Therapeutics BTAI	-3.52 M	$ 1.19	5.31 %	$ 14.5 M	USA
Burford Capital Limited BUR	99.1 M	$ 4.37	0.23 %	$ 958 M	Britain
I-Mab IMAB	722 K	-	-	$ 866 M	China
BeyondSpring BYSI	17 K	$ 0.84	34.27 %	$ 34.5 M	USA
AgeX Therapeutics AGE	51 K	-	-10.17 %	$ 12.2 K	USA
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
Cerus Corporation CERS	3.02 M	$ 2.98	4.93 %	$ 568 M	USA
Compugen Ltd. CGEN	281 K	$ 2.41	4.17 %	$ 225 M	Israel
Athira Pharma ATHA	1.24 M	-	-	$ 269 M	USA
Galera Therapeutics GRTX	11.4 M	-	-32.59 %	$ 7.61 M	USA
Hepion Pharmaceuticals HEPA	9.46 K	-	-18.79 %	$ 39.3 K	USA
ARCA biopharma ABIO	-12 K	-	1052.0 %	$ 415 M	USA
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Champions Oncology CSBR	211 K	$ 5.1	2.63 %	$ 70.5 M	USA
AnPac Bio-Medical Science Co., Ltd. ANPC	236 K	-	-1.58 %	$ 28.1 M	China
Adial Pharmaceuticals ADIL	165 K	$ 3.98	1.86 %	$ 2.66 M	USA
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
AnaptysBio ANAB	5.43 M	$ 58.47	4.37 %	$ 1.68 B	USA
Cyclacel Pharmaceuticals CYCCP	354 K	-	-4.36 %	$ 27 M	USA
Gracell Biotechnologies GRCL	6.74 M	-	-	$ 3.37 B	China
Aurinia Pharmaceuticals AUPH	2.78 M	$ 15.47	1.91 %	$ 2.08 B	Canada
GlycoMimetics GLYC	651 K	-	9357.83 %	$ 1.01 B	USA
AVROBIO AVRO	-119 K	-	1083.1 %	$ 745 M	USA
BeiGene, Ltd. BGNE	-42.6 M	-	0.49 %	$ 251 B	Cayman-islands
Bicycle Therapeutics plc BCYC	3.26 M	$ 3.9	0.24 %	$ 270 M	Britain
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
BioMarin Pharmaceutical BMRN	17.3 M	$ 67.36	0.99 %	$ 12.9 B	USA